Enhancing Cardiac Resynchronization Therapy for Patients with Atrial Fibrillation: The Role of AV Node Ablation
- PMID: 28496731
- PMCID: PMC5153197
- DOI: 10.4022/jafib.438
Enhancing Cardiac Resynchronization Therapy for Patients with Atrial Fibrillation: The Role of AV Node Ablation
Abstract
Cardiac resynchronization therapy (CRT) has evolved as an effective therapy for patients with congestive heart failure (CHF) and ventricular dyssynchrony, currently defined as a wide QRS on the electrocardiogram. While multiple randomized controlled trials have confirmed the favorable effects of CRT on mortality and heart failure symptoms for patients in sinus rhythm, only recently observational studies have begun to suggest a similar benefit for patients with atrial fibrillation (AF) and dyssynchrony. Yet, implementing effective biventricular pacing in patients with AF can be problematic due to competing intrinsic AV conduction. For patients with depressed ejection fractions needing AV node (AVN) ablation to control fast ventricular rates, biventricular pacing has been shown to be superior to right ventricular pacing alone. When consistent pacing (over 90% of the time) cannot be achieved in AF patients due to a rapid ventricular response despite pharmacological therapy, AVN ablation should be considered. The additional benefit of performing AVN ablation to promote biventricular pacing in patients without rapid ventricular rates remains uncertain. A randomized controlled trial is needed to test the incremental benefit of AVN ablation to promote biventricular pacing in heart failure patients with AF and wide QRS.
Similar articles
-
A strategy to achieve CRT response in permanent atrial fibrillation without obligatory atrioventricular node ablation.Pacing Clin Electrophysiol. 2012 Aug;35(8):943-7. doi: 10.1111/j.1540-8159.2012.03433.x. Epub 2012 May 31. Pacing Clin Electrophysiol. 2012. PMID: 22650352 Clinical Trial.
-
Rate or Rhythm Control in CRT (RHYTHMIC): Study rationale and protocol.Heart Rhythm O2. 2022 Sep 13;3(6Part A):681-687. doi: 10.1016/j.hroo.2022.09.001. eCollection 2022 Dec. Heart Rhythm O2. 2022. PMID: 36589918 Free PMC article.
-
Atrioventricular nodal ablation predicts survival benefit in patients with atrial fibrillation receiving cardiac resynchronization therapy.Heart Rhythm. 2010 Sep;7(9):1240-5. doi: 10.1016/j.hrthm.2010.02.011. Epub 2010 Feb 13. Heart Rhythm. 2010. PMID: 20156595
-
Role of Atrio-Ventricular Junction Ablation in Symptomatic Atrial Fibrillation for Optimization of Cardiac Resynchronization Therapy.J Atr Fibrillation. 2013 Apr 6;5(6):787. doi: 10.4022/jafib.787. eCollection 2013 Apr-May. J Atr Fibrillation. 2013. PMID: 28496831 Free PMC article. Review.
-
Atrioventricular Junction Ablation In Atrial Fibrillation: Choosing The Right Patient And Pacing Device.J Atr Fibrillation. 2015 Aug 31;8(2):1253. doi: 10.4022/jafib.1253. eCollection 2015 Aug-Sep. J Atr Fibrillation. 2015. PMID: 27957188 Free PMC article. Review.
References
-
- Roger Véronique L, Go Alan S, Lloyd-Jones Donald M, Adams Robert J, Berry Jarett D, Brown Todd M, Carnethon Mercedes R, Dai Shifan, de Simone Giovanni, Ford Earl S, Fox Caroline S, Fullerton Heather J, Gillespie Cathleen, Greenlund Kurt J, Hailpern Susan M, Heit John A, Ho P Michael, Howard Virginia J, Kissela Brett M, Kittner Steven J, Lackland Daniel T, Lichtman Judith H, Lisabeth Lynda D, Makuc Diane M, Marcus Gregory M, Marelli Ariane, Matchar David B, McDermott Mary M, Meigs James B, Moy Claudia S, Mozaffarian Dariush, Mussolino Michael E, Nichol Graham, Paynter Nina P, Rosamond Wayne D, Sorlie Paul D, Stafford Randall S, Turan Tanya N, Turner Melanie B, Wong Nathan D, Wylie-Rosett Judith. Heart disease and stroke statistics--2011 update: a report from the American Heart Association. Circulation. 2011 Feb 01;123 (4):e18–e209. - PMC - PubMed
-
- Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N. Engl. J. Med. 1991 Aug 01;325 (5):293–302. - PubMed
-
- Pitt B, Zannad F, Remme W J, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med. 1999 Sep 02;341 (10):709–17. - PubMed
-
- Pfeffer M A, Braunwald E, Moyé L A, Basta L, Brown E J, Cuddy T E, Davis B R, Geltman E M, Goldman S, Flaker G C. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N. Engl. J. Med. 1992 Sep 03;327 (10):669–77. - PubMed
-
- Hjalmarson A, Goldstein S, Fagerberg B, Wedel H, Waagstein F, Kjekshus J, Wikstrand J, El Allaf D, Vítovec J, Aldershvile J, Halinen M, Dietz R, Neuhaus K L, Jánosi A, Thorgeirsson G, Dunselman P H, Gullestad L, Kuch J, Herlitz J, Rickenbacher P, Ball S, Gottlieb S, Deedwania P. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA. 2000 Mar 08;283 (10):1295–302. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Research Materials